Psoriasis News and Research

Latest Psoriasis News and Research

RA patients who adhere to their prescription drug regimen have better outcome: Study

RA patients who adhere to their prescription drug regimen have better outcome: Study

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Discovery may yield better understanding of protective gut-dwelling bacteria

Discovery may yield better understanding of protective gut-dwelling bacteria

Research programme to develop immunological biomarkers for chronic inflammatory diseases

Research programme to develop immunological biomarkers for chronic inflammatory diseases

National Biological to market Quantel's 308 Excimer System in the U.S.

National Biological to market Quantel's 308 Excimer System in the U.S.

NexMed completes its post hoc analysis of NM100060

NexMed completes its post hoc analysis of NM100060

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough receives FDA recommendation approval for PEGINTRON

Kevetrin reduces tumor volume by 72%: Cellceutix

Kevetrin reduces tumor volume by 72%: Cellceutix

New consumer At-Home Skin Typing and Analysis Kit unveiled

New consumer At-Home Skin Typing and Analysis Kit unveiled

avVaa World Health Care Products launches Neuroskin Psoriasis Relief DRTV media test campaign

avVaa World Health Care Products launches Neuroskin Psoriasis Relief DRTV media test campaign

GVK Biosciences and Quantitative Solutions to develop and market clinical trial outcome databases

GVK Biosciences and Quantitative Solutions to develop and market clinical trial outcome databases

Two-thirds of women say psoriasis negatively affects their overall emotional well-being

Two-thirds of women say psoriasis negatively affects their overall emotional well-being

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Welichem announces filing of clinical trial application with Health Canada

Welichem announces filing of clinical trial application with Health Canada

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.